Published in Gene Therapy Weekly, May 10th, 2001
A. Kroger and colleagues investigated the use of IFR-1 as an agent for gene therapy in the treatment of highly malignant hepatocellular carcinoma (HCC). They created a fusion protein between IFR-1 and the human estrogen receptor protein (hER), which is activated by beta-estradiol (E2).
Kroger et al. stably transfected IFR-1hER genes into Hepa1-6, an HCC cell line. Before activation with E2, these cells expressed low levels of MHCI, high levels of CD54, and lacked MHCII, CD80, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.